Hikma Pharmaceuticals PLC HKMPY
46.68 USD -1.07 (-2.24%)
Nov 5, 2026, 11:18 AM EST
46.68 Day range 46.68
31.80 52-week range 47.75
- YTD
- +11.33%
- 1 year
- -0.68%
- Market cap
- 4.83B
- EPS (ttm)
- 3.52
- P/E ratio
- 13.26
- YTD return
- +11.33%
- 1-year return
- -0.68%
- Volume
- 1
- Avg volume
- 262
- Open
- 46.68
- Previous close
- 47.75
- Day's range
- 46.68 – 46.68
- 52-week range
- 31.80 – 47.75
2Y -0.05 (-0.11%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2026 | Dec 31, 2025 | — | 1.48 | — | — |
| Aug 7, 2025 | Jun 30, 2025 | — | 2.14 | — | — |
| Feb 26, 2025 | Dec 31, 2024 | — | 0.59 | — | — |
| Aug 8, 2024 | Jun 30, 2024 | — | 1.01 | — | — |
| Apr 25, 2024 | Dec 31, 2023 | — | 0.524 | — | — |
| Jun 29, 2023 | Jun 30, 2023 | — | 1.18 | — | — |
News
Hikma Pharmaceuticals PLC (HKMPY) Q3 2026 Sales/Trading Call Transcript 
Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown 
Hikma Pharmaceuticals PLC (HKMPY) Discusses R&D Vision and Expansion in Respiratory, Nasal, Semi-Solids and Liquid Platforms Transcript 
Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress 
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Transcript 
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Prepared Remarks Transcript 
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma 
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million 
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript 
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Your note
Sign in to keep a note on HKMPY — it syncs with the Stock Master app.